GLMDGalmed Pharmaceuticals Ltd
GLMD
Galmed Pharmaceuticals Ltd7,436
Mkt Cap
$3.96MVolume
32.0052W High
$2.3452W Low
$0.4111PE Ratio
-0.25GLMD Fundamentals
Price
$0.5827Prev Close
$0.60Open
$0.6150D MA
$0.6185Beta
1.35Avg. Volume
8.87MEPS (Annual)
-$2.39P/B
0.24Rev/Employee
$0.00$15.04
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA...
PR Newswire·5d ago
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics Tissue Dynamics and Galmed Pharmaceuticals to Develop...
PR Newswire·13d ago
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for...
PR Newswire·1mo ago
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain penetrating new formulation of Aramchol.read more...
Benzinga·1mo ago
These Stocks are Turning Heads
A wave of innovation across AI robotics, biotechnology, advanced materials, and clean energy is reshaping the small-cap landscape. $ONCO, $KBLB, $ELAB, $GLMD, $TURB, $GAME
24-7 Market News·1mo ago
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol Galmed Announces the Breakthrough Development of a Brain Penetrating New...
PR Newswire·1mo ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...
PR Newswire·2mo ago
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel, Jan...
PR Newswire·4mo ago
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR...
PR Newswire·5mo ago
<
1
2
...
>